Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination

Glen E. Cooke, Yiwen Liu-Stratton, Amy K. Ferketich, Melvin L. Moeschberger, David J. Frid, Raymond D. Magorien, Paul F. Bray, Philip F. Binkley, Pascal Goldschmidt-Clermont

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

OBJECTIVES: We studied the modifier effect of platelet antigen polymorphism (PlA2) on platelet inhibition by acetylsalicylic acid (ASA, i.e., aspirin), clopidogrel, or their combination in patients with coronary heart disease. BACKGROUND: Clopidogrel, when administered with ASA, was shown to significantly improve the outcome of patients with acute coronary syndromes compared with patients receiving only ASA. We have shown previously that the effect of ASA on platelets is modified by the glycoprotein IIIa single nucleotide polymorphism PlA2. Hence, an important pharmacogenetic question remains whether the antiplatelet effect of clopidogrel is uniform for all patients or, like acetylsalicylic acid, more selective. METHODS: Thirty PlA1/A1 and 30 PlA1/A2 patients were assigned randomly to ASA 325 mg/day, clopidogrel 75 mg/day, or both. After 10 days, platelet function was studied. RESULTS: Clopidogrel provided stronger platelet inhibition than ASA with adenosine diphosphate as the agonist, and combination therapy resulted in greater inhibition than either inhibitor used alone (p < 0.0001). The use of ASA resulted in greater inhibition compared with clopidogrel with epinephrine (p < 0.0001) and collagen as agonists (p < 0.0001). With collagen as the agonist, platelets from PlA1/A2 donors were markedly and significantly less inhibited by ASA (p = 0.005). In contrast, with clopidogrel, no significant difference could be detected between inhibition of Pl A1/A1 and PlA1/A2 platelets. CONCLUSIONS: The combination of ASA and clopidogrel appears superior to either agent alone in inhibiting platelet function. PlA2 functions as an important modifier for platelet responsiveness to ASA but not to clopidogrel. These findings could have significant impact on the future design of pharmacogenetic antithrombotic strategies for patients with coronary heart disease.

Original languageEnglish
Pages (from-to)541-546
Number of pages6
JournalJournal of the American College of Cardiology
Volume47
Issue number3
DOIs
StatePublished - Feb 7 2006
Externally publishedYes

Fingerprint

clopidogrel
Aspirin
Blood Platelets
Antigens
varespladib methyl
Pharmacogenetics
Coronary Disease
Collagen
Acute Coronary Syndrome

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Cooke, G. E., Liu-Stratton, Y., Ferketich, A. K., Moeschberger, M. L., Frid, D. J., Magorien, R. D., ... Goldschmidt-Clermont, P. (2006). Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination. Journal of the American College of Cardiology, 47(3), 541-546. https://doi.org/10.1016/j.jacc.2005.09.034

Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination. / Cooke, Glen E.; Liu-Stratton, Yiwen; Ferketich, Amy K.; Moeschberger, Melvin L.; Frid, David J.; Magorien, Raymond D.; Bray, Paul F.; Binkley, Philip F.; Goldschmidt-Clermont, Pascal.

In: Journal of the American College of Cardiology, Vol. 47, No. 3, 07.02.2006, p. 541-546.

Research output: Contribution to journalArticle

Cooke, GE, Liu-Stratton, Y, Ferketich, AK, Moeschberger, ML, Frid, DJ, Magorien, RD, Bray, PF, Binkley, PF & Goldschmidt-Clermont, P 2006, 'Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination', Journal of the American College of Cardiology, vol. 47, no. 3, pp. 541-546. https://doi.org/10.1016/j.jacc.2005.09.034
Cooke, Glen E. ; Liu-Stratton, Yiwen ; Ferketich, Amy K. ; Moeschberger, Melvin L. ; Frid, David J. ; Magorien, Raymond D. ; Bray, Paul F. ; Binkley, Philip F. ; Goldschmidt-Clermont, Pascal. / Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination. In: Journal of the American College of Cardiology. 2006 ; Vol. 47, No. 3. pp. 541-546.
@article{ff63324700ed4e06bc31686b92ab2eaa,
title = "Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination",
abstract = "OBJECTIVES: We studied the modifier effect of platelet antigen polymorphism (PlA2) on platelet inhibition by acetylsalicylic acid (ASA, i.e., aspirin), clopidogrel, or their combination in patients with coronary heart disease. BACKGROUND: Clopidogrel, when administered with ASA, was shown to significantly improve the outcome of patients with acute coronary syndromes compared with patients receiving only ASA. We have shown previously that the effect of ASA on platelets is modified by the glycoprotein IIIa single nucleotide polymorphism PlA2. Hence, an important pharmacogenetic question remains whether the antiplatelet effect of clopidogrel is uniform for all patients or, like acetylsalicylic acid, more selective. METHODS: Thirty PlA1/A1 and 30 PlA1/A2 patients were assigned randomly to ASA 325 mg/day, clopidogrel 75 mg/day, or both. After 10 days, platelet function was studied. RESULTS: Clopidogrel provided stronger platelet inhibition than ASA with adenosine diphosphate as the agonist, and combination therapy resulted in greater inhibition than either inhibitor used alone (p < 0.0001). The use of ASA resulted in greater inhibition compared with clopidogrel with epinephrine (p < 0.0001) and collagen as agonists (p < 0.0001). With collagen as the agonist, platelets from PlA1/A2 donors were markedly and significantly less inhibited by ASA (p = 0.005). In contrast, with clopidogrel, no significant difference could be detected between inhibition of Pl A1/A1 and PlA1/A2 platelets. CONCLUSIONS: The combination of ASA and clopidogrel appears superior to either agent alone in inhibiting platelet function. PlA2 functions as an important modifier for platelet responsiveness to ASA but not to clopidogrel. These findings could have significant impact on the future design of pharmacogenetic antithrombotic strategies for patients with coronary heart disease.",
author = "Cooke, {Glen E.} and Yiwen Liu-Stratton and Ferketich, {Amy K.} and Moeschberger, {Melvin L.} and Frid, {David J.} and Magorien, {Raymond D.} and Bray, {Paul F.} and Binkley, {Philip F.} and Pascal Goldschmidt-Clermont",
year = "2006",
month = "2",
day = "7",
doi = "10.1016/j.jacc.2005.09.034",
language = "English",
volume = "47",
pages = "541--546",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination

AU - Cooke, Glen E.

AU - Liu-Stratton, Yiwen

AU - Ferketich, Amy K.

AU - Moeschberger, Melvin L.

AU - Frid, David J.

AU - Magorien, Raymond D.

AU - Bray, Paul F.

AU - Binkley, Philip F.

AU - Goldschmidt-Clermont, Pascal

PY - 2006/2/7

Y1 - 2006/2/7

N2 - OBJECTIVES: We studied the modifier effect of platelet antigen polymorphism (PlA2) on platelet inhibition by acetylsalicylic acid (ASA, i.e., aspirin), clopidogrel, or their combination in patients with coronary heart disease. BACKGROUND: Clopidogrel, when administered with ASA, was shown to significantly improve the outcome of patients with acute coronary syndromes compared with patients receiving only ASA. We have shown previously that the effect of ASA on platelets is modified by the glycoprotein IIIa single nucleotide polymorphism PlA2. Hence, an important pharmacogenetic question remains whether the antiplatelet effect of clopidogrel is uniform for all patients or, like acetylsalicylic acid, more selective. METHODS: Thirty PlA1/A1 and 30 PlA1/A2 patients were assigned randomly to ASA 325 mg/day, clopidogrel 75 mg/day, or both. After 10 days, platelet function was studied. RESULTS: Clopidogrel provided stronger platelet inhibition than ASA with adenosine diphosphate as the agonist, and combination therapy resulted in greater inhibition than either inhibitor used alone (p < 0.0001). The use of ASA resulted in greater inhibition compared with clopidogrel with epinephrine (p < 0.0001) and collagen as agonists (p < 0.0001). With collagen as the agonist, platelets from PlA1/A2 donors were markedly and significantly less inhibited by ASA (p = 0.005). In contrast, with clopidogrel, no significant difference could be detected between inhibition of Pl A1/A1 and PlA1/A2 platelets. CONCLUSIONS: The combination of ASA and clopidogrel appears superior to either agent alone in inhibiting platelet function. PlA2 functions as an important modifier for platelet responsiveness to ASA but not to clopidogrel. These findings could have significant impact on the future design of pharmacogenetic antithrombotic strategies for patients with coronary heart disease.

AB - OBJECTIVES: We studied the modifier effect of platelet antigen polymorphism (PlA2) on platelet inhibition by acetylsalicylic acid (ASA, i.e., aspirin), clopidogrel, or their combination in patients with coronary heart disease. BACKGROUND: Clopidogrel, when administered with ASA, was shown to significantly improve the outcome of patients with acute coronary syndromes compared with patients receiving only ASA. We have shown previously that the effect of ASA on platelets is modified by the glycoprotein IIIa single nucleotide polymorphism PlA2. Hence, an important pharmacogenetic question remains whether the antiplatelet effect of clopidogrel is uniform for all patients or, like acetylsalicylic acid, more selective. METHODS: Thirty PlA1/A1 and 30 PlA1/A2 patients were assigned randomly to ASA 325 mg/day, clopidogrel 75 mg/day, or both. After 10 days, platelet function was studied. RESULTS: Clopidogrel provided stronger platelet inhibition than ASA with adenosine diphosphate as the agonist, and combination therapy resulted in greater inhibition than either inhibitor used alone (p < 0.0001). The use of ASA resulted in greater inhibition compared with clopidogrel with epinephrine (p < 0.0001) and collagen as agonists (p < 0.0001). With collagen as the agonist, platelets from PlA1/A2 donors were markedly and significantly less inhibited by ASA (p = 0.005). In contrast, with clopidogrel, no significant difference could be detected between inhibition of Pl A1/A1 and PlA1/A2 platelets. CONCLUSIONS: The combination of ASA and clopidogrel appears superior to either agent alone in inhibiting platelet function. PlA2 functions as an important modifier for platelet responsiveness to ASA but not to clopidogrel. These findings could have significant impact on the future design of pharmacogenetic antithrombotic strategies for patients with coronary heart disease.

UR - http://www.scopus.com/inward/record.url?scp=31644438586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31644438586&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2005.09.034

DO - 10.1016/j.jacc.2005.09.034

M3 - Article

C2 - 16458133

AN - SCOPUS:31644438586

VL - 47

SP - 541

EP - 546

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 3

ER -